Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the launch and growth potential of its drug Rytelo (imetelstat) between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Geron misled investors regarding the expectations for Rytelo's market performance, downplaying risks associated with the drug's monitoring requirements and competition [2]. - Following the announcement of Geron's fourth-quarter financial results for fiscal 2024 on February 26, 2025, which revealed a flattening growth for Rytelo, the company's stock price dropped from $2.37 to $1.61 per share, a decline of approximately 32.07% in one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified period have until May 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, of the May 12, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2] - The lead plaintiff must file a motion with the court by May 12, 2025, to represent other class members [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in recovering funds [3] Group 3: Case Allegations - The lawsuit alleges that Geron Corporation made false or misleading statements regarding the market potential of its drug RYTELO, leading to overstated business and financial prospects [4] - Specific claims include a lack of awareness among healthcare providers, a weekly monitoring requirement, and competition that would impair the drug's profitability [4] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements [4]

Core Viewpoint - A class action has been filed against Geron Corporation for allegedly misleading investors about the launch and growth potential of its drug Rytelo, leading to a significant decline in stock price following disappointing financial results [1][2][3]. Group 1: Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancer treatment, with its primary product being a telomerase inhibitor called imetelstat, marketed as Rytelo [1]. Group 2: Allegations and Financial Impact - The complaint alleges that Geron failed to disclose critical factors affecting Rytelo's market performance, including seasonality, competition, and lack of awareness, which contributed to a failure to meet growth expectations [2]. - On February 26, 2025, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, and monitoring requirements, resulting in a stock price drop from $2.37 to $1.61, a decline of approximately 32.07% in one day [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Geron, with a deadline to file as lead plaintiff by May 12, 2025. Participation is not required to be eligible for recovery [4]. Group 4: Legal Representation - Robbins LLP, a firm specializing in shareholder rights litigation, represents the class action on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, about the May 12, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Geron securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the court by May 12, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that Geron Corporation made false and misleading statements regarding the launch of its drug RYTELO, claiming that various factors would impair its profitability [4] - Specific claims include a lack of awareness among healthcare providers, the requirement for weekly monitoring, and competition affecting Geron's ability to meet market needs [4] - As a result of these misrepresentations, Geron's business and financial prospects were overstated, leading to investor damages when the truth was revealed [4]

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/geron-corporation-lawsuit ...

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period [1][3]. Group 1: Allegations Against Geron Corporation - Defendants allegedly created a false impression of reliable information regarding Geron's revenue outlook and growth potential while downplaying risks from seasonality and macroeconomic factors [3]. - Reports on the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions, competition, and patient initiation challenges [3]. - RYTELO reportedly lacked market awareness, hindering Geron's ability to meet the significant unmet need for the drug, particularly among first-line patients and those outside academic settings [3]. - Statements made by the defendants regarding the company's business and prospects were alleged to be materially false and misleading [3]. Group 2: Legal Process for Investors - Geron investors have until May 12, 2025, to seek appointment as lead plaintiff representatives in the class action through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [4]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [4].

RADNOR, Pa., April 18, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation ("Geron") (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is May 12, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Geron losses, you may ...

NEW YORK, April 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/geron-corporation-lawsuit-submi ...

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=143339&from=4CLASS PERIOD: February 28, 202 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Geron between February 28, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 13, 2025 (GLOBE ...